542.08

1.11% 5.97

After Hours: 542.08

Argen X Se Adr (ARGX)

Overview News Price History Option Chain Why ARGX Down? Discussions Forecast

Argen X Se Adr stock is traded at $542.08, with a volume of 159.35K. It is up +1.11% in the last 24 hours and up +4.79% over the past month. Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Previous Close:

$536.11

Open:

$536.38

24h Volume:

159.35K

Relative Volume:

0.50

Market Cap:

$32.26B

Revenue:

$1.62B

Net Income/Loss:

$-204.35M

P/E Ratio:

-130.31

EPS:

-4.16

Net Cash Flow:

$-1.28B

1W Performance:

+2.57%

1M Performance:

+4.79%

6M Performance:

+37.68%

1Y Performance:

+10.26%

1-Day Range:

$536.00

$544.73

1-Week Range:

$512.01

$550.62

52-Week Range:

$327.73

$554.74

Argen X Se Adr Stock (ARGX) Company Profile

Name

Argen X Se Adr

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

Address

Employee

1,148

Twitter

Next Earnings Date

2024-07-25

Latest SEC Filings

ARGX's Discussions on Twitter

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	Deutsche Bank	Buy → Hold
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jul-31-23	Initiated	Scotiabank	Sector Perform
Jul-24-23	Downgrade	UBS	Buy → Neutral
Jul-17-23	Resumed	Evercore ISI	Outperform
Jun-15-23	Initiated	Societe Generale	Sell
May-31-23	Initiated	UBS	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-14-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-07-22	Initiated	William Blair	Outperform
Oct-12-22	Initiated	Oppenheimer	Perform
Jul-29-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-22	Resumed	Stifel	Buy
May-03-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Upgrade	Piper Sandler	Neutral → Overweight
Oct-29-21	Upgrade	Guggenheim	Neutral → Buy
Oct-28-21	Upgrade	Raymond James	Outperform → Strong Buy
Oct-07-21	Initiated	Jefferies	Buy
Sep-23-21	Upgrade	Redburn	Neutral → Buy
Sep-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-23-21	Initiated	Deutsche Bank	Hold
Jul-19-21	Resumed	Wolfe Research	Outperform
Jun-18-21	Initiated	UBS	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-23-21	Initiated	Redburn	Neutral
Mar-05-21	Reiterated	H.C. Wainwright	Neutral
Feb-02-21	Downgrade	Piper Sandler	Overweight → Neutral
Jan-04-21	Downgrade	Guggenheim	Buy → Neutral
Aug-25-20	Initiated	Raymond James	Outperform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-20	Initiated	H.C. Wainwright	Neutral
Feb-10-20	Initiated	BofA/Merrill	Buy
Nov-05-19	Initiated	Credit Suisse	Neutral
Oct-31-19	Upgrade	William Blair	Mkt Perform → Outperform
Oct-22-19	Initiated	JP Morgan	Overweight
Sep-27-19	Initiated	Wells Fargo	Market Perform
Sep-16-19	Resumed	Cowen	Outperform
Jun-28-19	Initiated	Robert W. Baird	Outperform
Jan-18-19	Resumed	SunTrust	Buy
Jan-04-19	Initiated	Morgan Stanley	Overweight
Dec-17-18	Initiated	Goldman	Buy
Dec-14-18	Initiated	Wolfe Research	Outperform
Jun-29-18	Initiated	Nomura	Buy
Apr-09-18	Initiated	SunTrust	Buy
Jan-29-18	Reiterated	JMP Securities	Mkt Outperform

View All

Argen X Se Adr Stock (ARGX) Latest News

11:51 AM

Weekly Upgrades and Downgrades - InvestorPlace

11:51 AM

Sep 25, 2024

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases - Investor's Business Daily

Sep 25, 2024

Baird sustains price target on Argenx shares, cites competition - Investing.com

Sep 25, 2024

Piper Sandler maintains Overweight rating on argenx shares - Investing.com

Sep 25, 2024

Sep 19, 2024

argenx ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

Sep 19, 2024

Sep 06, 2024